Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Friday, December 18, 2009, 2:56PM ET - U.S. Markets close in 1 hour and 4 minutes. Dow Down 0.03% Nasdaq Up 1.11%
NOVOGEN FPO (NRT.AX)On Dec 17: 0.510  Down 0.040 (7.27%)  
MORE ON NRT.AX
Quotes
Charts
News & Info
HereHeadlines
Company
Analyst Coverage
Ownership
Financials

HeadlinesGet Headlines for:
Change Display [ hide $$  edit ]
Tue, Dec 1, 2009
Marshall Edwards, Inc. Appoints Acting CEO
Marketwire (Tue, Dec 1)
Tue, Sep 29, 2009
Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo
Marketwire (Tue, Sep 29)
Tue, Sep 22, 2009
Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
Marketwire (Tue, Sep 22)
Wed, Aug 5, 2009
Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
Marketwire (Wed, Aug 5)
Thu, Jul 30, 2009
Novogen Director Retires
Marketwire (Thu, Jul 30)
Tue, Jul 7, 2009
Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells
Marketwire (Tue, Jul 7)
Wed, Jun 17, 2009
Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
Marketwire (Wed, Jun 17)
Mon, Apr 20, 2009
Novogen's NV-128 Targets the mTOR Pathway to Block Differentiation and Induce Cell Death in Ovarian Cancer Stem Cells
Marketwire (Mon, Apr 20)
Tue, Apr 14, 2009
Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
Marketwire (Tue, Apr 14)
Mon, Mar 23, 2009
Board Changes at Novogen Limited Announced
Marketwire (Mon, Mar 23)
Thu, Mar 19, 2009
Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
Marketwire (Thu, Mar 19)
Wed, Mar 18, 2009
Novogen's NV-128 Targets the mTOR Pathway to Induce Cell Death in Epithelial Ovarian Cancer Stem Cells
Marketwire (Wed, Mar 18)
Triphendiol Safety Data Clears the Way for Compound to Be Studied Further in the Treatment of Pancreatic Cancer
Marketwire (Wed, Mar 18)
Tue, Feb 24, 2009
Yale Researchers Present Results of Phase II Phenoxodiol Clinical Trial in Prostate Cancer Patients at ASCO 2009 Genitourinary Cancers Symposium
Marketwire (Tue, Feb 24)
Fri, Feb 13, 2009
Novogen to Focus on Oncology Program
Marketwire (Fri, Feb 13)
Wed, Jan 14, 2009
Marshall Edwards, Inc. to Present at the 27th Annual JPMorgan Healthcare Conference
Marketwire (Wed, Jan 14)
Wed, Jan 7, 2009
Marshall Edwards, Inc. Granted IND for Triphendiol
Marketwire (Wed, Jan 7)
Fri, Dec 19, 2008
Marshall Edwards, Inc. Announces Resignation of Stephen Breckenridge From Board of Directors and Appointment of William Rueckert as Chairman of Audit Committee
Marketwire (Fri, Dec 19)
Older Headlines - Download Recent Headlines
View headlines from:
Add NRT.AX News to My Yahoo!:
Add to My Yahoo! View RSS Feed

Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
Get Headlines for Another Symbol: Symbol Lookup
Stocks In PlayStory Stocks
Full Coverage